Bristol-Myers Squibb Services Unlimited Company — Sponsor Intelligence | 91 EU Trials

Filter these 91 trials by condition, phase, country and more.

Open in Search →

91 Registered trials

48 Recruiting

36 Completed trials

22 Countries active

85 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 46 Phase II/III: 9 Phase II: 12 Phase I/II: 4 Phase III/IV: 1 Phase I: 5 Phase I (Other): 6 Phase I (FiH): 8

Oversight events:

14 temporary halts 2 unexpected events 4 corrective measures across 10 trials

View oversight register →

100%

36 of 36 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 6 Dementia Alzheimer's type 6 Non-small cell lung cancer metastatic 5 Mania 4 Non-small cell lung cancer recurrent 3 Systemic lupus erythematosus 3 Subacute cutaneous lupus erythematosus 2 Idiopathic pulmonary fibrosis 2 Schizophrenia 2 Pulmonary fibrosis 2 Rheumatoid arthritis 2 Hepatocellular carcinoma 2

Top IMPs

NIVOLUMAB 23 TROSPIUM CHLORIDE, XANOMELINE TARTRATE 12 DEUCRAVACITINIB 11 IPILIMUMAB 8 NIVOLUMAB, RELATLIMAB 6 PUMITAMIG 6 XANOMELINE TARTRATE 6 IZALONTAMAB BRENGITECAN 4 ADMILPARANT 3 CISPLATIN 3 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE 2 BEVACIZUMAB 2

All trials

91 total

A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer Pending

2024-513987-24-00 Phase I 1 country
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 Phase II/III 10 countries IZALONTAMAB BRENGITECAN
A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending

2025-522373-10-00 Phase III 14 countries ADMILPARANT
A Phase 1/2a Study of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies Pending

2025-523547-35-00 Phase I (FiH) 1 country BMS-986523
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending

2025-523711-11-00 Phase III 1 country TROSPIUM CHLORIDE, XANOMELINE TARTRATE
Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending

2025-524062-16-00 Phase III 1 country TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with … Pending

2025-524285-18-00 Phase II 4 countries NAVLIMETOSTAT; PUMITAMIG
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants Pending

2025-524564-38-00 Phase I (Other) 1 country
A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer Recruiting

2025-524090-16-00 Phase I (FiH) 3 countries BMS-986525; NIVOLUMAB
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Phase III 14 countries PUMITAMIG
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting

2025-523586-18-00 Phase III 16 countries PUMITAMIG
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting

2024-519994-20-00 Phase III 11 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refrac… Recruiting

2024-519537-29-00 Phase I 2 countries
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 Phase III 6 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy… Recruiting

2025-521511-40-00 Phase II/III 15 countries NAVLIMETOSTAT
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520195-94-00 Phase III 5 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Phase III 11 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Phase I (FiH) 2 countries BMS-986470
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi… Recruiting

2022-501332-42-00 Phase III 5 countries OZANIMOD HYDROCHLORIDE
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Phase III 15 countries ADMILPARANT
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Phase III 15 countries ADMILPARANT
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Phase III 10 countries CRIZOTINIB; REPOTRECTINIB
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting

2022-500700-22-00 Phase III 7 countries DEUCRAVACITINIB
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting

2023-509248-86-00 Phase II/III 5 countries OZANIMOD

Showing 1–24 of 91 trials

← All sponsors A–Z